Additional Information
Manakamana Khanal received her Ph.D. from the University of Lille, France in Biomedical Engineering. Her research at NCI focuses on enhancement of anti-tumor efficacy of CAR T cells against mesothelioma, a difficult to treat solid tumor, using immunotoxin (LMB100) that targets mesothelin (MSLN). She is also involved in a collaborative project aiming to develop CAR T cells targeting MSLN peptide MHC (pMHC) complexes. She likes hiking, watching movies and cooking in her free time.
Area of Expertise:
- Enhancement of CAR T cells efficacy 2. Solid tumor 3. Immunotoxin 4. MSLN peptide MHC complexes